Share this article
Share this article
ResearchAndMarkets.com s offering.
This research service provides an overview of the orphan drugs market dynamics, estimating the market size broken down by different segments. It also dives deeper into the different technological, geographical, and therapeutic opportunities with an objective assessment of the disclosed pipelines. Notably, the study has an expanded coverage of not only rare diseases, but also hard-to-cure and commercially non-viable diseases.
Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregivers, and centers of excellence (COEs).
Coffee may cut heart failure risk
But benefits come from caffeinated java, analysis shows By American Heart Association News
Published: February 16, 2021, 5:11am
Share:
Drinking one or more cups of coffee a day may reduce the risk of heart failure, according to new research. But only if it’s caffeinated.
The analysis of data from three large, well-known heart disease trials was published in the American Heart Association journal Circulation: Heart Failure. It found the more coffee people drank, the lower their risk for heart failure. But that benefit didn’t extend to people who drank decaf.
“The association between caffeine and heart failure risk reduction was surprising,” senior author Dr. David Kao said in a news release. Kao is an assistant professor of cardiology and medical director at the Colorado Center for Personalized Medicine at the University of Colorado School of Medicine in Aurora.
BioIVT, a leading provider of research models and services for drug and diagnostic development, today introduced its COVID-19 Vaccination Panel, composed of pre- and post-vaccination serum or PBMC samples, to enable researchers to study blood donors’ vaccine-generated immune response.
BioIVT has been providing more than 300 clients with biospecimens to support the development of COVID-19 diagnostic assays and therapeutic interventions since the beginning of the pandemic. Those biospecimens have included saliva, serum, plasma, PBMCs, fresh whole blood, bulk plasma, and bulk serum from acute COVID-19 cases and recovered donors, together with representative diagnostic polymerase chain reaction or serological antibody test results to verify infection and /or exposure. BioIVT samples are provided with donor social, demographic and co-morbidity data, together with the date of onset, symptoms, and severity of their COVID-19 infection where available.
While Europe mulls multiple praiseworthy schemes to limit the damage inflicted by cancer, one of the most promising avenues is being neglected – and many Europeans are dying unnecessarily as a consequence. Lung cancer, the biggest cancer killer, is still on the loose, largely unchecked, and the most effective method for combating it – screening […]